A novel human foamy virus mediated gene transfer of GAD67 reduces neuropathic pain following spinal cord injury

Neuropathic pain is a long-lasting clinical problem that is often refractory to medical management. Gene transfer of specific genes for therapeutic benefit offers a novel approach to the treatment of neuropathic pain. In this study, we tested whether the transfer of the glutamic acid decarboxylase (...

Full description

Saved in:
Bibliographic Details
Published in:Neuroscience letters 2008-02, Vol.432 (1), p.13-18
Main Authors: Liu, Wanhong, Liu, Zhongchun, Liu, Li, Xiao, Zheman, Cao, Xiongbin, Cao, Zhijian, Xue, Lu, Miao, Lixia, He, Xiaohua, Li, Wenxin
Format: Article
Language:English
Subjects:
Animals
Behavior, Animal
Biological and medical sciences
Fundamental and applied biological sciences. Psychology
GAD
gamma-Aminobutyric Acid - physiology
Ganglia, Spinal - physiology
Gene therapy
Gene Transfer Techniques
Genetic Therapy - methods
Glutamate Decarboxylase - genetics
HFV
Hyperalgesia - etiology
Hyperalgesia - therapy
Injections, Subcutaneous
Male
Neuralgia - etiology
Neuralgia - therapy
Neuropathic pain
Rats
Rats, Sprague-Dawley
Spinal Cord Injuries - complications
Spumavirus - genetics
Vertebrates: nervous system and sense organs
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Neuropathic pain is a long-lasting clinical problem that is often refractory to medical management. Gene transfer of specific genes for therapeutic benefit offers a novel approach to the treatment of neuropathic pain. In this study, we tested whether the transfer of the glutamic acid decarboxylase (GAD) gene to dorsal root ganglion (DRG) cells would attenuate below-injury level central neuropathic pain after spinal cord injury (SCI) by using a novel human foamy virus (HFV) vector to achieve release of gamma-aminobutyric acid (GABA). Subcutaneous inoculation of a replication-defective HFV vector, which expresses GAD (vector rdvGAD67) for 7 days after T13 spinal cord hemisection, reversed mechanical allodynia and thermal hyperalgesia evoked by SCI. The antiallodynic effect lasted 6 weeks and was reestablished by reinoculation. We also found that subcutaneous inoculation of rdvGAD67 resulted in enhanced production of GAD and tonical GABA release from transduced DRG neurons. These results suggest that HFV-mediated gene transfer to DRG could be employed to treat below-injury level central neuropathic pain after incomplete SCI.
ISSN:0304-3940
1872-7972
DOI:10.1016/j.neulet.2007.11.054